Brief: Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference
12/01/2026 13:17
Jan 12 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES 2026 OUTLOOK AHEAD OF 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NUVATION BIO INC - PRELIM IBTROZI NET PRODUCT REVENUE $15.7 MILLION IN Q4 Source text: ID:nBw59kBJBa Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth